Nexstim Oyj
5.3.2021 08:01:54 CET | Globenewswire | Press release
Company announcement, Helsinki, 5 March 2021 at 09.00 am (EET)
Nexstim Plc Publishes 2020 Annual Report
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the publication of its 2020 Annual Report. These documents are available on the "Investor Relations" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations.
The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement.
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
certifiedadviser@penser.se
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
F. Hoffmann-La Roche Ltd20.2.2026 07:00:00 CET | Press release
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
dsm-firmenich20.2.2026 07:00:00 CET | Press release
dsm-firmenich publishes 2025 Integrated Annual Report
Sika AG20.2.2026 05:00:00 CET | Press release
SIKA REPORTS FULL-YEAR 2025 RESULTS – EXECUTING PLAN TO ACCELERATE GROWTH
WillScot19.2.2026 22:05:00 CET | Press release
WillScot Reports Fourth Quarter and Full Year 2025 Results and Provides 2026 Outlook
WillScot19.2.2026 22:02:00 CET | Press release
WillScot Declares Quarterly Cash Dividend
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
